Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $49.3M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +4 vs. previous quarter
- 27
- 13F valueReported value at the end of Q2 2026
- $32.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $43.8M
- +589.9% year over year
- Net income, FY2025
- -$35.0M
- No comparable prior period
- Free cash flow, FY2025
- -$5.51M
- No comparable prior period
- Revenue, Q2 FY2026
- $18.7M
- +131.2% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $35.0M (80.1% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 382.8K
- Shares sold short
- Change
- −17.6K
- −4.4% vs. previous
- Days to cover
- 20.30
- At average daily volume
Superinvestors holding XLO, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding XLO at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Xilio Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 (view filing) | Mar 26 | 4 days | Shannon James SamuelDirector | PPurchase | +5.00K | $8.79 | +$44.0K | +100.0%10.0K after | |
| Feb 17, 2026 (view filing) | Feb 13 | 4 days | Gilead Sciences, Inc.10% Owner | PPurchase | +3.74M | $0.53 | +$1.98M | –40.4M after | Derivative |
| Jan 5, 2026 (view filing) | Jan 2 | 3 days | Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | SSale | −1.83K | $0.64 | −$1.17K | −22.3%6.37K after | 10b5-1 |
| Jan 5, 2026 (view filing) | Jan 2 | 3 days | Frankenfield Christopher JamesChief Financial Officer | SSale | −7.03K | $0.64 | −$4.50K | −22.1%24.8K after | 10b5-1 |
| Jun 18, 2025 (view filing) | Jun 16-17 | 2 days | Shannon James SamuelDirector | PPurchase | +70.0K | $0.69 | +$48.3K | New position70.0K after | 2 lots |
| Jun 18, 2025 (view filing) | Jun 16 | 2 days | Russo RenePRESIDENT AND CEO | PPurchase | +36.3K | $0.68 | +$24.7K | +14.8%281.2K after | |
| Jun 6, 2025 (view filing) | Jun 5 | 1 day | Gilead Sciences, Inc.10% Owner | PPurchase | +53.3M | – | – | –13.3M after | Derivative4 lots |
| Jan 3, 2025 (view filing) | Jan 2 | 1 day | Frankenfield Christopher JamesChief Financial Officer | SSale | −6.95K | $0.98 | −$6.81K | −35.9%12.4K after | 10b5-1 |
| Jan 3, 2025 (view filing) | Jan 2 | 1 day | Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | SSale | −1.80K | $0.98 | −$1.77K | −36.1%3.20K after | 10b5-1 |
| Dec 19, 2024 (view filing) | Dec 18 | 1 day | Gilead Sciences, Inc.10% Owner | PPurchase | +1.76M | $1.04 | +$1.83M | +24.0%9.11M after |
Top 10 13F holders, Q2 2026
See all 27 holdersThe largest institutional positions in Xilio Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 664,021 | $6.36M | 0.38% | 00.0% | Unchanged |
| Gilead Sciences, Inc. | 650,389 | $6.23M | 0.38% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 592,300 | $5.67M | 0.11% | +592,300 | New |
| Frazier Life Sciences Management, L.P. | 422,505 | $4.05M | 0.09% | 00.0% | Unchanged |
| Stonepine Capital Management, LLC | 225,994 | $2.17M | 1.65% | +161,832+252.2% | Added |
| Vanguard Capital Management LLC | 178,517 | $1.71M | 0.00% | +54,857+44.4% | Added |
| Sio Capital Management, LLC | 152,464 | $1.46M | 0.25% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 111,541 | $1.07M | 0.00% | +111,541 | New |
| Merck & Co., Inc. | 105,982 | $1.02M | 0.19% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 64,153 | $614.6K | 0.00% | +14,587+29.4% | Added |
Holders of 5% or more of XLO
See all 9 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Xilio Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 13G/A | 19.90%14.5M shares | 0.00 ppfrom 19.90% | Apr 5, 20244 filings | Feb 12, 2026 | SEC |
| Coastlands Capital LP | 13G | 9.99%5.35M shares | New | Dec 11, 20251 filing | Dec 11, 2025 | SEC |
| Bain Capital Life Sciences Fund II, L.P. | 13G/A | 9.99%664.0K shares | – | May 15, 20261 filing | May 15, 2026 | SEC |
| OrbiMed Advisors LLC | 13G | 9.99%642.0K shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| Sirenia Capital Management LP | 13G | 9.90%1.14M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |